Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension

Boehringer Ingelheim19,870 enrolled

Overview

This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.

Study Type

OBSERVATIONAL

Enrollment

19,870

Conditions

Hypertension

Interventions

Micardis®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of both sexes with essential hypertension and a minimum age of 18 years Exclusion Criteria: (Not applicable)